Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease

[Image: see text] Galectin-3 is a carbohydrate-binding protein central to regulating mechanisms of diseases such as fibrosis, cancer, metabolic, inflammatory, and heart disease. We recently found a high affinity (nM) thiodigalactoside GB0139 which currently is in clinical development (PhIIb) as an i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zetterberg, Fredrik R., MacKinnon, Alison, Brimert, Thomas, Gravelle, Lise, Johnsson, Richard E., Kahl-Knutson, Barbro, Leffler, Hakon, Nilsson, Ulf J., Pedersen, Anders, Peterson, Kristoffer, Roper, James A., Schambye, Hans, Slack, Robert J., Tantawi, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574852/
https://www.ncbi.nlm.nih.gov/pubmed/36154172
http://dx.doi.org/10.1021/acs.jmedchem.2c00660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574852/
https://www.ncbi.nlm.nih.gov/pubmed/36154172
http://dx.doi.org/10.1021/acs.jmedchem.2c00660

Ejemplares similares